Drugs /

doxorubicin

Back to Drugs List

Overview

Generic Name(s):
doxorubicin
Trade Name(s):
Adriamycin Pfs, Doxolem, Rubex, Doxorubin, Farmiblastina, Adrimedac, Adriacin, Adriamycin Rdf, Adriblastine, Adriblastina, and Doxo-Cell
NCI Definition [1]:
An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.

Clinical Trials

View Clinical Trials for doxorubicin

Doxorubicin has been investigated in 205 clinical trials, of which 173 are open and 32 are closed. Of the trials investigating doxorubicin, 5 are early phase 1 (5 open), 34 are phase 1 (22 open), 25 are phase 1/phase 2 (21 open), 88 are phase 2 (76 open), 6 are phase 2/phase 3 (4 open), 44 are phase 3 (43 open), and 3 are no phase specified (2 open).

HER2 Deficient Expression, HER2 Negative, and ER Negative are the most frequent biomarker inclusion criteria for doxorubicin clinical trials.

Breast carcinoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia are the most common diseases being investigated in doxorubicin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Doxorubicin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Doxorubicin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating doxorubicin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
hydroxydaunorubicin, Adriamycin PFS, Adriamycin RDF, Adriacin, Adriblastina, Rubex, Farmiblastina, Doxorubin, Doxolem, DOXO-CELL, Adrimedac, Adriblastine
Drug Categories [2]:
Topoisomerase II inhibitors
NCIT ID [1]:
C456

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.